Definium's CEO said the company expects to file an NDA for DT120 in the first half of next year after three positive pivotal readouts in generalized anxiety disorder and major depressive disorder. A second major depressive disorder pivotal readout is expected in 2027.
DFTX · Definium Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Definium Therapeutics reported three positive phase three readouts for DT120—two in GAD and one in MDD—and plans to submit an NDA to FDA in the first half of next year for both indications.
Definium Therapeutics reported three positive phase 3 studies for DT120 in GAD and MDD, plans an NDA filing in the first half of 2027, and expects approximately $1.05 billion in cash and investments to fund operations into 2030.
Definium Therapeutics’ DT120 Phase 3 trials met primary and key secondary endpoints in generalized anxiety disorder and major depressive disorder; approximately $1.0 billion in cash and investments at September 30, 2026 is expected to fund operations into 2030.
Definium Therapeutics reported positive Phase 3 DT120 ODT results, FDA Breakthrough Therapy Designation in major depressive disorder, and approximately $1.05 billion in cash as of September 30, 2026. It plans an NDA filing in the first half of 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Nov 9, 2026TL;DR. DT120 delivered consistent Phase 3 results across three studies, received an MDD Breakthrough Therapy designation, remains on track for a first-half 2027 NDA filing, and is supported by approximately $1.05 billion in liquidity; DT402 showed positive initial results and commercial preparation is advancing. R&D and G&A spending increased year over year, while DT402’s five-participant study had exploratory endpoints and was not powered to draw statistical conclusions.
- + DT120 produced consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD.
- + DT120 ODT received FDA Breakthrough Therapy designation in MDD.
- + DT120 ODT remains on track for an NDA filing in the first half of 2027.
- + Cash, cash equivalents and investments were approximately $1.05 billion and are expected to fund operations into 2030.
- + DT402 showed positive initial results in its Phase 2a trial, with a multiple-dosing study planned for 2027.
- + Commercial readiness activities and organizational capabilities are advancing toward commercialization.
- − Third-quarter 2026 R&D expenses increased to $46.1 million from $31.0 million in the prior-year period.
- − Third-quarter 2026 G&A expenses increased to $26.1 million from $14.7 million in the prior-year period.
- − DT402’s five-participant Phase 2a study had exploratory endpoints and was not powered to draw statistical conclusions.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and investments | $1.1B | As of June 30, 2026 | — |
| DT120 GAD external research and development expenses | 22.65M | the three months ended June 30, 2026 filing | — |
| DT120 MDD external research and development expenses | 7.21M | the three months ended June 30, 2026 filing | — |
| DT120 other external research and development expenses | 3.7M | the three months ended June 30, 2026 filing | — |
| DT402 program external research and development expenses | 444K | the three months ended June 30, 2026 filing | — |
| Internal research and development costs | 13.41M | the three months ended June 30, 2026 filing | — |
| MADRS: LS mean change at Week 12 (DT120 ODT 100 µg) | -11 | the three months ended June 30, 2026 filing | — |
| MADRS: LS mean change at Week 12 (Placebo ODT) | -3.6 | the three months ended June 30, 2026 filing | — |
| MADRS: LS mean change at Week 6 (DT120 ODT 100 µg) | -13.3 | the three months ended June 30, 2026 filing | — |
| MADRS: LS mean change at Week 6 (Placebo ODT) | -5.2 | the three months ended June 30, 2026 filing | — |
| MADRS: remission rate (≤12) at Week 6 (DT120 ODT 100 µg) | 24% | the three months ended June 30, 2026 filing | — |
| MADRS: remission rate (≤12) at Week 6 (Placebo ODT) | 3% | the three months ended June 30, 2026 filing | — |
| MADRS: response rate (≥50%) at Week 6 (DT120 ODT 100 µg) | 35% | the three months ended June 30, 2026 filing | — |
| MADRS: response rate (≥50%) at Week 6 (Placebo ODT) | 7% | the three months ended June 30, 2026 filing | — |
| Preclinical and other programs external research and development expenses | 1.26M | the three months ended June 30, 2026 filing | — |
| Total DT120 program external research and development expenses | 33.56M | the three months ended June 30, 2026 filing | — |
| Total external research and development expenses | 35.26M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DFTX
this stock
Definium Therapeutics, Inc.
|
$3.99B | +117.5% | — | — | 7.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 23
Definium's CEO said the company expects to file an NDA for DT120 in the first half of next year after three positive pivotal readouts in generalized anxiety disorder and major depressive disorder. A second major depressive disorder pivotal readout is expected in 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DFTX | -15.5% | -18.0% | +20.4% | -19.9% | +117.5% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -11.6% | -12.4% | +23.9% | -16.5% | +110.4% |